Phospho-SNCA (Y136) Antibody

What is the biological significance of Y136 phosphorylation in alpha-synuclein?

Alpha-synuclein (SNCA) is a neuronal protein that plays several crucial roles in synaptic activity, including regulation of synaptic vesicle trafficking and subsequent neurotransmitter release. It participates as a monomer in synaptic vesicle exocytosis by enhancing vesicle priming, fusion, and dilation of exocytotic fusion pores. The protein also acts as a molecular chaperone in its multimeric membrane-bound state, assisting in the folding of synaptic fusion components called SNAREs at the presynaptic plasma membrane in conjunction with cysteine string protein-alpha/DNAJC5 .

While phosphorylation at S129 has been extensively studied in relation to pathology, Y136 phosphorylation represents another important post-translational modification (PTM) site within the C-terminal region. Y136 phosphorylation may influence protein-protein interactions and potentially modulate alpha-synuclein's physiological functions or pathological aggregation. Understanding this specific modification provides valuable insights into the complex regulation of alpha-synuclein in both normal and disease states.

How do Y136 phospho-specific antibodies compare to other alpha-synuclein phosphorylation site antibodies?

Alpha-synuclein contains multiple phosphorylation sites that have been studied using specific antibodies, including S129, Y125, Y39, S87, and Y136. While S129 phosphorylation has received the most attention due to its enrichment in Lewy bodies, antibodies targeting other sites provide complementary information about alpha-synuclein biology .

Phospho-Y136 antibodies target a less studied but potentially important modification in the C-terminal region. Unlike the more abundant pS129 antibodies (which include commercial options like MJF-R13, 81A, pSyn#64, and EP1536Y), fewer Y136 phospho-specific antibodies are currently available . The Y136 antibodies typically consist of rabbit polyclonal preparations suitable for Western blot and immunocytochemistry/immunofluorescence applications with human and mouse samples .

When selecting between different phospho-specific antibodies, researchers should consider the specific research question, available validation data, and the potential for cross-reactivity or sensitivity to neighboring modifications, which can significantly impact experimental results and interpretations.

What validation steps should be performed before using a phospho-Y136 antibody in experiments?

Before employing a phospho-Y136 antibody in crucial experiments, several rigorous validation steps should be conducted to ensure reliable results:

• Epitope specificity verification: Test the antibody against recombinant alpha-synuclein proteins with and without Y136 phosphorylation to confirm specificity for the modified form. This approach was demonstrated in comprehensive validation studies for other alpha-synuclein antibodies .

• Knockout control testing: Validate the antibody using alpha-synuclein knockout (KO) mouse neurons and brain tissues to identify any non-specific signals, as several phospho-specific antibodies have shown non-specific staining in KO tissues .

• Cross-reactivity assessment: Examine potential cross-reactivity with other phosphorylated proteins, particularly those with similar sequence motifs around tyrosine residues.

• Neighboring PTM sensitivity testing: Determine whether the antibody's binding is affected by post-translational modifications at nearby residues. This is crucial as studies have shown that some antibodies fail to recognize their target when adjacent residues are modified .

• Method-specific validation: Verify antibody performance in each specific application (Western blot, immunohistochemistry, etc.) as antibodies may perform differently across various techniques.

What experimental controls are essential when using phospho-Y136 antibodies?

When designing experiments with phospho-Y136 antibodies, the following controls are critical:

• Positive controls: Include recombinant alpha-synuclein specifically phosphorylated at Y136. Semi-synthetic approaches similar to those used for generating pY125 and pS129 standards can provide reliable positive controls .

• Negative controls: Incorporate non-phosphorylated alpha-synuclein and alpha-synuclein knockout samples to identify non-specific signals. Studies have shown that even commonly used phospho-specific antibodies can produce false positive signals in KO tissues .

• Dephosphorylation controls: Treat duplicate samples with phosphatases to demonstrate phosphorylation-dependent antibody binding.

• Peptide competition assays: Pre-incubate the antibody with phosphorylated and non-phosphorylated peptides to confirm epitope specificity.

• Multiple antibody verification: When possible, confirm results using two independent phospho-Y136 antibodies or alternative approaches to detect this modification.

How can researchers address potential cross-reactivity of phospho-Y136 antibodies with other phosphorylated proteins?

Cross-reactivity is a significant concern with phospho-specific antibodies. To address this issue with phospho-Y136 antibodies, researchers should implement a multi-faceted approach:

• Sequential immunodepletion: Perform immunoprecipitation with the phospho-Y136 antibody, followed by immunoblotting with total alpha-synuclein antibodies and vice versa to confirm that the detected signals represent the same protein.

• Mass spectrometry validation: Confirm the presence of phospho-Y136 in immunoprecipitated samples using mass spectrometry, which can provide unambiguous identification of the modified protein and site.

• Two-dimensional gel electrophoresis: Separate proteins by both isoelectric point and molecular weight to distinguish alpha-synuclein from potential cross-reactive species.

• Parallel analysis with knockout models: Always include alpha-synuclein knockout samples as negative controls, as studies have shown that even well-characterized phospho-specific antibodies can produce signals in knockout tissues .

• Signal abolishment by competing phosphopeptides: Pre-incubate antibodies with the phospho-Y136 peptide immunogen to block specific binding, which should eliminate true phospho-Y136 signals but not cross-reactive signals.

Implementing these approaches can significantly improve confidence in the specificity of detected signals and prevent misinterpretation of data due to antibody cross-reactivity with other phosphorylated proteins.

How do neighboring post-translational modifications affect phospho-Y136 antibody recognition?

The impact of neighboring post-translational modifications (PTMs) on antibody binding is a critical consideration when working with phospho-specific antibodies. Based on studies with other alpha-synuclein phospho-antibodies, we can infer important principles for phospho-Y136 antibodies:

• Proximity effects: PTMs near the Y136 site may sterically hinder antibody binding or alter the local peptide conformation. For example, studies have shown that C-terminal antibodies targeting regions 115-125, 120-125, 121-132, and 123-125 failed to produce strong signals when Y125 was phosphorylated .

• Multi-site phosphorylation interference: Multiple phosphorylation events can create interference patterns. For instance, the MJF-R13 antibody could detect singly phosphorylated pS129 but not di-phosphorylated pY125/pS129-aSyn, while the pSyn#64 antibody detected both forms .

• Truncation sensitivity: C-terminal truncations can eliminate epitopes or change protein conformation. As observed with other antibodies, the AB 134-138 antibody showed no positive signal when alpha-synuclein was truncated at residue 135 .

To address these concerns, researchers should:

• Test antibody recognition using recombinant proteins with various combinations of PTMs

• Create a sensitivity profile documenting how nearby modifications affect antibody binding

• Consider using multiple antibodies targeting different epitopes when studying complex biological samples

Understanding these interaction patterns is essential for accurate interpretation of experimental results, particularly in disease states where multiple PTMs may co-occur on alpha-synuclein.

How can phospho-Y136 antibodies be incorporated into multiplexed detection strategies for different alpha-synuclein proteoforms?

Multiplexed detection of alpha-synuclein proteoforms offers a powerful approach to understanding the complex landscape of modifications in health and disease. Phospho-Y136 antibodies can be strategically incorporated into such systems through:

• Sequential immunolabeling protocols: Employ antibodies raised in different host species (rabbit anti-phospho-Y136 combined with mouse anti-phospho-S129) with species-specific secondary antibodies for simultaneous detection of multiple PTMs on the same tissue sections or blots .

• Multi-epitope profiling: Combine phospho-Y136 antibodies with antibodies targeting other regions (N-terminal, NAC, and C-terminal) to obtain a comprehensive view of alpha-synuclein modifications. This approach revealed distinct and heterogeneously modified alpha-synuclein pathologies in previous studies .

• Fluorescence multiplexing: Utilize spectral unmixing and multi-round immunofluorescence to detect numerous modifications simultaneously. This technique can be particularly valuable for studying co-localization patterns of different PTMs.

• Proximity ligation assays: Apply this technique to detect when two different modifications (e.g., phospho-Y136 and phospho-S129) occur on the same protein molecule, providing insight into co-modification patterns.

• Mass cytometry adaptation: Adapt antibodies for use in mass cytometry (CyTOF) by metal-conjugation for highly multiplexed single-cell analysis of alpha-synuclein proteoforms.

These approaches enable researchers to move beyond studying individual modifications in isolation and instead examine the complex interplay between different alpha-synuclein proteoforms in various cellular contexts and disease states.

What are the challenges in quantifying phospho-Y136 alpha-synuclein in biological samples, and how can they be addressed?

Accurate quantification of phospho-Y136 alpha-synuclein in biological samples presents several technical challenges:

• Low abundance issue: Phosphorylated forms typically represent a small fraction of total alpha-synuclein. To address this, researchers should:

  • Implement phospho-enrichment strategies (e.g., phospho-tyrosine immunoprecipitation followed by alpha-synuclein detection)

  • Use high-sensitivity detection methods such as enhanced chemiluminescence or fluorescence-based Western blotting

• Signal normalization complexity: When comparing across samples, normalization approaches must account for variations in total alpha-synuclein levels. Solutions include:

  • Calculating phospho-Y136/total alpha-synuclein ratios using parallel blots or sequential reprobing

  • Employing absolute quantification with purified phospho-Y136 standards of known concentration

• Sample preparation artifacts: Postmortem changes and extraction methods can alter phosphorylation status. Researchers should:

  • Document and standardize post-collection intervals

  • Include phosphatase inhibitors throughout sample processing

  • Compare results from multiple extraction methods to identify potential artifacts

• Cross-reactivity and specificity issues: As discussed previously, antibody cross-reactivity can confound quantification. Implement:

  • Rigorous validation with knockout controls and peptide competition assays

  • Orthogonal verification using mass spectrometry-based approaches

• Assay dynamic range limitations: Ensure that measurements fall within the linear range of detection by:

  • Establishing standard curves with recombinant phospho-Y136 alpha-synuclein

  • Preparing serial dilutions of samples to identify the optimal loading amount

Addressing these challenges is essential for generating reliable quantitative data on phospho-Y136 alpha-synuclein levels in biological samples from control and disease states.

What are common sources of false positives/negatives when using phospho-Y136 antibodies, and how can they be identified?

When working with phospho-Y136 antibodies, several common sources of experimental artifacts can lead to misinterpretation:

False Positives:

• Cross-reactivity with other phospho-proteins: Other proteins containing similar phospho-tyrosine motifs may be detected by the antibody. This can be identified through:

  • Testing in alpha-synuclein knockout tissues, where signals should be absent

  • Parallel immunoblotting for alpha-synuclein to confirm molecular weight

  • Pre-absorption with phospho-Y136 peptide to eliminate specific signals

• Non-specific secondary antibody binding: Secondary antibodies may bind endogenous immunoglobulins. Identify by:

  • Including secondary-only controls

  • Testing in different buffer conditions to minimize non-specific interactions

• Endogenous phosphatase inactivation: Inadequate phosphatase inhibition during sample preparation can generate artifactual phosphorylation. Address by:

  • Comparing fresh vs. delayed sample processing to assess time-dependent changes

  • Systematically testing different phosphatase inhibitor cocktails

False Negatives:

• Epitope masking by protein interactions: Protein binding partners may block antibody access to the phospho-Y136 site. Identify through:

  • Comparing native vs. denaturing conditions

  • Testing different extraction methods with varying detergent strengths

• Sensitivity to neighboring PTMs: As observed with other phospho-antibodies, modifications at adjacent sites may prevent recognition . Assess by:

  • Testing antibody against recombinant proteins with defined modification patterns

  • Using multiple antibodies targeting different epitopes around the same site

• Rapid dephosphorylation during processing: Y136 phosphorylation may be labile. Address by:

  • Comparing immediate fixation vs. delayed processing

  • Testing phosphatase inhibitor effectiveness specifically for tyrosine phosphatases

Understanding these potential artifacts is crucial for accurate data interpretation and experimental troubleshooting when working with phospho-Y136 antibodies.

How should researchers interpret conflicting results between different detection methods for phospho-Y136 alpha-synuclein?

When faced with discrepant results between different detection methods for phospho-Y136 alpha-synuclein, researchers should implement a systematic approach to reconcile these differences:

• Method-specific limitations assessment:

  • Western blotting may detect denatured epitopes not accessible in fixed tissues

  • Immunohistochemistry preserves spatial information but may suffer from cross-reactivity

  • Mass spectrometry offers high specificity but lower sensitivity for low-abundance modifications

  Create a table documenting the strengths and weaknesses of each method to guide interpretation.

• Sample preparation differences:

  • Extraction buffers can differentially solubilize alpha-synuclein proteoforms

  • Fixation methods may preserve or mask certain epitopes

  Standardize preparation protocols across methods when possible or explicitly acknowledge these differences.

• Antibody-specific characteristics:

  • Different clones may recognize distinct sub-epitopes within the phospho-Y136 region

  • Sensitivity to neighboring modifications varies between antibodies

  Use multiple antibodies and compare their validation profiles.

• Quantitative vs. qualitative discrepancies analysis:

  • Determine if differences are in absolute detection (present/absent) or relative abundance

  • Establish detection thresholds for each method

  Plot correlation analyses between methods to identify systematic biases.

• Biological vs. technical variation distinction:

  • Repeat experiments to assess reproducibility

  • Include biological replicates to capture natural variation

  Use statistical approaches appropriate for the specific methods being compared.

When publishing conflicting results, researchers should transparently report methodological details and limitations rather than selecting only concordant data. This approach not only improves scientific rigor but also advances understanding of the complex biology of alpha-synuclein modifications.

How might phospho-Y136 antibodies contribute to understanding the role of alpha-synuclein in neurodegenerative disease progression?

Phospho-Y136 antibodies offer unique opportunities to advance our understanding of alpha-synuclein's role in neurodegenerative diseases through several promising research directions:

• Temporal profiling of modification patterns: By combining phospho-Y136 antibodies with those targeting other modifications like phospho-S129, researchers can establish the sequence of modifications during disease progression. This approach, similar to that used with expanded antibody panels , could reveal whether Y136 phosphorylation is an early or late event in pathology formation.

• Cell type-specific phosphorylation patterns: Different neural cell populations may exhibit distinct alpha-synuclein modification profiles. Multiplexed immunofluorescence with phospho-Y136 and cell-type markers could reveal cell-specific vulnerabilities or protective mechanisms.

• Correlation with disease subtypes: Various synucleinopathies (Parkinson's disease, dementia with Lewy bodies, multiple system atrophy) display different pathological manifestations. Systematic profiling of phospho-Y136 levels could identify disease-specific signatures that might inform differential diagnosis or mechanism-based therapeutic approaches.

• Relationship to other PTMs: Developing a comprehensive map of how Y136 phosphorylation correlates with other modifications would provide insight into potential cross-talk mechanisms. Previous studies have shown that neighboring PTMs can significantly influence antibody detection , suggesting complex interrelationships between modification sites.

• Biomarker development: Validated phospho-Y136 antibodies could be employed in biofluid analyses to evaluate the potential of phospho-Y136 alpha-synuclein as a disease biomarker, complementing existing approaches focused primarily on phospho-S129.

These approaches collectively promise to expand our understanding beyond the dominant focus on phospho-S129 and provide a more nuanced view of alpha-synuclein's pathological roles.

What technological advances would improve the reliability and applications of phospho-Y136 antibodies in synucleinopathy research?

Several technological advances could significantly enhance the utility and reliability of phospho-Y136 antibodies for synucleinopathy research:

• Development of conformation-specific phospho-Y136 antibodies: Current antibodies primarily detect the linear epitope around Y136, but antibodies that specifically recognize phospho-Y136 in pathological conformations (similar to conformation-specific tau antibodies) would enable more precise characterization of disease-relevant species.

• Single-molecule detection platforms: Adapting phospho-Y136 antibodies for use in single-molecule detection systems would allow quantification of rare modification events and provide insights into the heterogeneity of alpha-synuclein populations within individual cells.

• Proximity-based modification detection: Developing split-reporter systems that generate signal only when specific combinations of modifications (e.g., pY136 and pS129) occur on the same molecule would advance our understanding of modification patterns in disease states.

• Intrabody development: Converting phospho-Y136 antibodies into intrabodies that function within living cells would enable real-time tracking of modification dynamics in cellular models of synucleinopathy.

• Cross-species validation platforms: Systematic validation across multiple model organisms and human samples would strengthen confidence in the biological relevance of findings. Recent approaches using knockout controls demonstrated the importance of such validation .

• Automated image analysis algorithms: Developing machine learning-based image analysis tools specifically trained to quantify phospho-Y136 signals would improve consistency in tissue analyses and enable high-throughput screening applications.